s
s
s
Develop highly selective and sensitive PK and ADA assays for the monoclonal antibody drug palivizumab (Synagis) using ready-made anti-idiotypic antibodies.
Table 1. Antibodies Specific to Palivizumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Palivizumab Inhibitory Type 1 |
HCA261 |
AbD23967 |
Fab-FH1 |
1.5 |
PK bridging ELISA |
|
HCA262 |
AbD23967_hlgG1 |
Human IgG1 HRP |
1.5 |
PK bridging ELISA ADA control |
* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody DYKDDDDK- and His-6-tags
Type 1 anti-palivizumab antibodies inhibit the binding of the drug palivizumab to its target, a highly conserved region on the F protein of respiratory syncytial virus (RSV). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. The antibody in fully human IgG1 format is suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
Fig. 1. Palivizumab PK bridging ELISA using antibodies HCA261 and HCA262P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 2. Palivizumab ADA bridging ELISA using antibody HCA262.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.